Press Releases

Date Title
4/8/19 Sarepta Therapeutics’ Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference
3/29/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/28/19 Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study
3/25/19 Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program
3/5/19 Sarepta Therapeutics Announces Pricing of $375.0 Million Public Offering of Common Stock
3/5/19 Sarepta Therapeutics Announces Proposed $350,000,000 Public Offering of Common Stock
2/28/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/28/19 Sarepta Therapeutics Announces Second Year of Route 79, The Duchenne Scholarship Program
2/27/19 Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments
2/27/19 Sarepta Therapeutics Announces Positive and Robust Expression and Biomarker Data from the First Three-Patient Cohort Dosed in the MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
Displaying 61 - 70 of 635